Since the 1980’s, there has been considerable hope MS IVIg treatments, or one of the other immunosuppressive agents could possibly successfully treat MS. Some of them have worked well, others have not. Multiple Sclerosis IVIg was once promising. Some of that initial hope has faded. For the most part the treatments for MS have evolved from immunosuppressive steroids and chemotherapy to the immunomodulators like Avonex, Betaseron, and Copaxone. Despite initial positive indications, these treatments have been mostly disappointing. And most of the long-term effects have been acutely toxic over long periods. It is now determined that these treatments should only be used in very select circumstances and patients. Multiple Sclerosis IVIg was once promising. Intravenous immunoglobulin G (IVIg) was once thought to reduce the clinical attack rate. But the initial trials involved only small numbers of patients, therefore once more comprehensive studies were conducted have challenged the validity of those initial trials.
Intravenous immunoglobulin G also used in the treatment of RRMS
Relapsing/Remitting Multiple Sclerosis was initially thought to be successfully treated. MS IVIg treatment findings were later found to be less effective, however when the trial group numbers were expanded. The reduction in clinical attack rates was less consistent and they were lacking in significant MRI outcome data. There has been so much variation in the results of the different studies that it is not really even possible to determine the proper dosage for Multiple Sclerosis IVIg therapy. It is now the general consensus that this type of therapy involving Intravenous immunoglobulin G should be avoided altogether except in very rare and select cases.
You might relieve your symptoms better simply by including aerobic exercise or diet changes as part of your treatment. Nutritional changes are more often being cited in the last few years as showing significant improvement in symptom relief. And at least you won’t have any side effects to worry about.
Multiple Sclerosis IVIg off-label
It bears noting that Multiple Sclerosis IVIg use is off off-label. That means that although the drug is approved for use, it is just not approved for use in treating MS. It just seems that there is not enough evidence to support the use of this drug for this disease. It is quite effective in treating Guillain-Barre syndrome and Myasthenia Gravis. So while the jury is still out, each patient will have to ask if this is an avenue they want to pursue when there are so many alternatives available. None of them provide a cure, but many show better results at relieving the symptoms of MS.
